Bls Pharmaceuticals (ASX:BLS)
ASX announcement history & article coverage
Transparent by design.
Announcments by Bls Pharmaceuticals (ASX:BLS) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Appendix 4G Corporate Governance Statement
BLS FY2027 Guidance
BLS Pharmaceuticals targets $105-$115 million revenue in FY2027 with strong growth and expanded manufacturing capacity
BLS Investor Presentation
BLS Pharmaceuticals delivers record FY26 results with strong international growth and $50m German supply deal
BLS FY2026 Results Announcement
BLS Pharmaceuticals reports record FY26 revenue and profit, secures $50 million German supply deal, expands international manufacturing
Annual Report to shareholders
BLS Pharmaceuticals reports record FY26 revenue and profit, expands international manufacturing and secures major contracts
BLS FY2026 Results Webinar 2 September 2026 8am AEST
Application for quotation of securities - BLS
BLS to Present at Coffee Microcaps 31/7/2026 at 11.30 am
BLS Pharmaceuticals Investor Webinar Presentation
BLS Pharmaceuticals reports record Q4 FY2026 revenue and cash flow, expands international GMP manufacturing platform
BLS Q4 FY2026 Results Investor Webinar
Quarterly Activities/Appendix 4C Cash Flow Report
BLS Pharmaceuticals reports record FY26 revenue and EBITDA, secures major international supply deals, and advances manufacturing expansion
Agreement with Trexapharm for Commercialisation of Trexavive
BLS Strengthens Gobal Psychedelic Medicines Platform